John Childs is a seasoned investor and philanthropist who has served on the boards of numerous public and private companies over the years—he will bring extensive operational and capital markets expertise to the Pyramid Biosciences team. Until his retirement in 2019, Mr. Childs served as the chairman and CEO of J.W. Childs Associates, L.P., a multibillion-dollar private equity firm with a particular emphasis on healthcare and consumer products, which he founded in 1995.
Prior to founding his own firm, Mr. Childs held various executive leadership roles at Thomas H. Lee Partners and at Prudential Insurance Company of America. Mr. Childs currently serves on the Board of Directors of Biohaven Pharmaceuticals (NYSE: BHVN), Kleo Pharmaceuticals, Omax Health, and Realm Cellars, and is also on the Board of Managers of the Jane Coffin Childs Memorial Fund for Medical Research. Mr. Childs holds a B.A. from Yale University and an MBA from Columbia University.